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Summary 
Background and objective We analyzed the urine samples of patients with type 2 
diabetes at various stages of diabetic nephropathy by lectin microarray to identify a 
biomarker to predict the progression of diabetic nephropathy.  
Design, setting, participants, & measurements Japanese patients with type 2 
diabetes at various stages of nephropathy were enrolled and we performed lectin 
microarray analyses (n=17) and measured urinary excretion of fetuin-A (n=85).  
Results The increased signals of urine samples were observed in 
Siaα2-6Gal/GalNAc-binding lectins (SNA, SSA, TJA-I) during the progression of 
diabetic nephropathy. We next isolated sialylated glycoproteins by using SSA-lectin 
affinity chromatography and identified fetuin-A by liquid chromatography–tandem mass 
spectrometer. Urinary excretion of fetuin-A significantly increased during the 
progression of albuminuria (A1, 0.40±0.43; A2, 0.60±0.53; A3 1.57±1.13 ng/gCr; 
p=7.29x10-8) and of GFR stages (G1, 0.39±0.39; G2, 0.49±0.45; G3, 1.25±1.18; G4, 
1.34±0.80 ng/gCr; p=3.89x10-4). Multivariate logistic regression analysis was employed 
to assess fetuin-A as a risk for diabetic nephropathy with microalbuminuria or GFR < 60 
mL/min. Fetuin-A is demonstrated as a risk factor for both microalbuminuria and 
reduction of GFR in diabetic nephropathy with the odds ratio of 4.721 (1.881-11.844) 
and 3.739 (1.785-7.841), respectively.  
Conclusions Collectively, the glycan profiling analysis is useful method to identify the 
urine biomarkers and fetuin-A is a candidate to predict the progression of diabetic 
nephropathy. 
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Introduction 
The most critical issue in clinical nephrology is relentless and progressive increase 
in the patients with end-stage renal disease (ESRD) in worldwide. The impact of 
diabetic nephropathy on the increasing population with chronic kidney disease (CKD) 
and ESRD is enormous. The intensified multifactorial intervention in patients with type 2 
diabetes mellitus resulted in reduced risk of microangiopathy, cardiovascular events and 
mortality in Steno type 2 randomized studies1; however, the incidence of ESRD is 
progressively increasing in worldwide. To predict the progression of diabetic 
nephropathy and cardiovascular outcome, the simultaneous evaluation of albuminuria 
and glomerular filtration rate (GFR) is recommended by the KDIGO: Kidney Disease 
Improving Global Outcomes CKD Work Group2. In The Action in Diabetes and Vascular 
Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) study, the 
measurements of albuminuria, eGFR or their combination predicted the cardiovascular 
events and death, and renal outcome3. In addition to the albuminuria at baseline, the 
changes of albuminuria further well-predicted mortality and cardiovascular and renal 
outcomes, independent of baseline albuminuria reported by ONTARGET investigators4. 
Although the repeated measurements of albuminuria is recommended in the clinical 
practice in diabetes, the presence of GFR decliners in both type 1 and type 2 diabetes 
has been reported. In type 1 diabetes, the GFR decliners with early reduction of GFR 
were reported in 9% of the patients with normoalbuminuria and 31% of 
microalbuminuria5. In the patients with type 2 diabetes, the rapid GFR decliners 
demonstrated the reduction of GFR although they were treated with olmesartan in 
addition to the angiotensin converting enzyme inhibitors. In such patients, it was difficult 
to predict the natural course of diabetic nephropathy by the combination of albuminuria 
and eGFR6. 
Based upon these clinical observations, we need to search more reliable urinary 
 4
biomarkers to predict both renal and cardiovascular outcome. The biomarkers of renal 
dysfunction such as transferrin, type IV collagen and N-acetyl-beta-D-glucosaminidase, 
inflammatory markers including orosomucoid, tumour necrosis factor-α, transforming 
growth factor-β, vascular endothelial growth factor and monocyte chemoattractant 
protein-1, as well as oxidative stress markers such as 8-hydroxy-2'deoxyguanosine may 
be more sensitive than urinary albumin, the current gold standard, in the detection of 
incipient nephropathy and risk assessment of cardiovascular disease; however, the 
sensitivity of these markers compared with albumin requires further investigation7.   
Recently, the urinary proteome analyses have been performed using 2-dementional 
gel electrophoresis and subsequent mass spectrometry to identify the novel urinary 
markers8-10; however, the identification of new markers may be suffered from 
contamination of urinary major proteins such as albumin, immunoglobulins, 
α1-antitrypsin, transferrin, and haptoglobin. In the line of considerations, we focused on 
the alterations of glycochains to identify useful urinary biomarkers. The changes in 
glycoproteome profile in the urine may be due to the alterations in the glycoprotein 
leakage into the urine by the damages of capillary selective permeability and also 
attributed to the high glucose-induced changes in the expression of the enzymes which 
are responsible to the glycochain modification. For example, increased hexosamine 
biosynthesis induced by high glucose conditions plays a key role in the development of 
insulin resistance in primary cultured adipocytes11 and the increased flux through the 
hexosamine biosynthetic pathway and subsequent enhanced O-linked glycosylation 
(N-acetylglucosamine [O-GlcNAc]) of proteins have been implicated in insulin 
resistance in skeletal muscle12. However, the glycoproteome profile has not been 
well-investigated because of the technical obstacles. We employed the evanescent-field 
fluorescence-assisted lectin microarray: a new strategy for glycan profiling, which allows 
sensitive, real-time observation of multiple lectin-carbohydrate interactions under 
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equilibrium conditions, to identify the changes in the functional glycans in a 
high-throughput manner13. We identified the increase in the biding activity to 
Siaα2-6-Gal/GalNAc in urine samples from the patients with diabetic nephropathy. We 
next identified fetuin-A, α1-microglobulin, and orosomucoid as sialylated glycoproteins 
and we found fetuin-A may be a useful urinary marker to predict the development of 
microalbuminuria and reduction of GFR in diabetic nephropathy. 
 
Materials and Methods 
Patients 
Urine samples of Japanese healthy subjects without type 2 diabetes (n=12) and 
Japanese patients with type 2 diabetes with various stages of normoalbuminuria (n=7), 
microalbuminuria (n=5) and macroalbuminuria (n=5) were obtained and subjected to 
lectin microarray studies. Based on the lectin microarray studies, we identified sialylated 
glycoproteins, such as fetuin-A, α1-microglobulin, and orosomucoid as candidate markers 
for diabetic nephropathy and we newly recruited Japanese patients with type 2 diabetes 
(n=85, 62.9 ± 11.3 years) into this study. The patients with type 2 diabetes were treated 
with oral hypoglycemic agents (n=48) and insulin treatment (n=49). The patients with 
eGFR < 15 ml/min/1.73 m2 or under dialysis were excluded from the current study. All 
recruited patients with type 2 diabetes agreed to perform lectin microarray of urine 
samples and measure urinary levels of fetuin-A, α1-microglobulin, and orosomucoid. The 
study was conducted in accordance with the ethical principle of the Declaration of 
Helsinki and approved by ethical committee of Okayama University Graduate School of 
Medicine, Dentistry and Pharmaceutical Sciences. We obtained informed consent from 
each patient. 
 
Lectin microarray 
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   Fifty mL of urine samples were concentrated by Centricon at 5,000 g for 40 min and 
further by Microcon at 14,000 g for 70 min to the volume of 0.5 mL (Millipore, Billerica, 
MA). Ten μL of concentrated urine samples were applied to Multiple Affinity Removal 
Spin Cartridge for Human Serum (Agilent Technologies, Santa Clara, CA) to remove 
major serum proteins such as albumin, IgG, α1-antitrypsin, IgA, transferrin, and 
haptoglobin. Five hundred μl of the effluents dialyzed against PBS were applied to 
ULTRAFREE 0.5 BIOMAX-5k (Millipore) and concentrated to final volume of 50 μL. 
Protein concentration was measured with MicroBCA Protein Assay Kit (Thermo 
Scientific Pierce, Rockford, IL) and the final concentration was adjusted to 50 μg/mL, in 
which 20 μL was incubated with Cy3 at room temperature for 1 hour. Cy3-labeled 
samples were applied to gel filtration columns (Zeba Desalt Spin Columns 0.5 ml, 
Thermo Scientific Pierce) and the samples with 2, 1, 0.5, 0.25, 0.125, 0.063, 0.031 
μg/mL were prepared with Probing Buffer and 100 μL / well of samples were applied to 
Lectin Array, LecChip (GP Biosciences, Tokyo, Japan) at 20oC for 15 hours. The lectin 
signals were measured with GlycostationTM Reader 1200 with exposure time (133 
msec) and gain (85, 95, 105, and 115). Scanned images of 16 bit TIFF were analyzed 
with Array-Pro Analyzer (MEDIA CYBERNETICS, Rockville, MD) and GlycoStation 
Tools (GP Biosciences). The list of lectins is indicated in the Supplemental Table 1 and 
blood group A antigen (HPA) and group B antigen (EEL) were excluded from the 
analysis. 
 
Isolation of sialylated urinary proteins in the patients with diabetic nephropathy 
Hundred mL of urine samples were concentrated by Centricon at 5,000 g for 40 min and 
further by Microcon at 14,000 g for 70 min to the volume of 1 mL. Affinity 
chromatography was performed using SSA-Agarose (Lectin-Agarose Set-III) and 
BioLogic LP system II (#731-8300X2, BIO-RAD, Hercules, CA). The SSA-Agarose 
 7
column was equilibrated by 6.0 mL of PBS at the flow rate of 0.2 mL/min. The 
concentrated urine samples of 1.0 mL were applied to the sample loop and PBS was 
loaded at 0.1 mL/min for 10 min. The SSA-Agarose column was washed with PBS at 
0.1 mL/min for 70 min. Five mL of the elution buffer (0.2 M lactose) was applied to 
sample loop and eluted with PBS at 0.1 mL/min for 60 min and further washed with PBS 
at 0.5 mL/min for 20 min.  While eluting the sialylated glycoproteins, the fractions of 0.5 
ml were collected every 5 min. The eluted samples were subjected to SDS-PAGE 
analysis and the proteins were identified by Liquid chromatography–tandem mass 
spectrometer (LC/MS-MS) analyses as follows. 
Cysteine bonds of the eluted glycoproteins were reduced by 10 mM dithiothreitol 
(DTT) at 56oC for 1 hour and alkylated with 50 mM iodoacetamide (IAA) at room 
temperature for 45 min at room temperature in the dark. They were enzymatically 
digested with 0.1 μg of sequencing grade trypsin at 30oC for overnight. The digested 
peptides were extracted once in 1% formic acid and subsequently twice in 5% formic 
acid and in 50% acetonitrite. Peptides were separated by nanoUPLC (nanoACQUITY 
UPLC, Waters, Milford, MA) and analyzed with Q-Tof micro (Waters). nanoUPLC was 
equipped with 5.0 μm Symmetry C18, 180 μmID×2 cm precolumn and 1.7 μm BEH 130 
C18, 100 μmID×10 cm column. Mobile phase A was water with 0.1% formic acid whilst 
mobile phase B was 0.1% formic acid in acetonitrile. Using MassLynx 4.1 (Waters) the 
MS/MS raw data were transformed into peak lists (.pklfiles) and they were searched 
thorough NCBInr and Swiss-Prot by using Mascot (Matrix Science, Boston, MA).  
 
Blood sampling and assays  
We measured overnight fasting serum levels of total cholesterol and low density 
lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, triglycerides (L 
Type Wako Triglyceride・H, Wako Chemical, Osaka, Japan), uric acid, serum creatinine 
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(Cr), serum urea nitrogen (UN), plasma glucose, and HbA1c. Urinary albumin was 
measured in random spot urine samples by standard immuno-nephelometric assay. The 
urinary albumin-creatinine ratio (ACR) was calculated. Estimated glomerular filtration 
rate (eGFR) was calculated by equation; eGFR (ml/min/1.73 m2)=194×Cr-1.094×age-0.287 
in male and eGFR (ml/min/1.73 m2)=194×Cr-1.094×age-0.287×0.739 in female14. By using 
the definition and classification of chronic kidney disease [Kidney Disease: Improving 
Global Outcomes (KDIGO)]2, all patients were classified into albuminuria and GFR 
category. In albuminuria stages, the patients were classified into three groups; A1 (<30 
mg/gCr), A2 (30-299 mg/gCr) and A3 (>300 mg/gCr). In GFR stages, they were 
classified into 4 groups; G1 (>90 ml/min/1.73 m2), G2 (60-89 ml/min/1.73 m2), G3 (30-59 
ml/min/1.73 m2), and G4 (15-29 ml/min/1.73 m2). Urinary excretions of fetuin-A, 
α1-microglobulin, and orosomucoid were measured with ELISA kit for Human Fetuin-A 
(BioVender, Modrice, Czech Republic), LZ Test Eiken α1-M (Eiken Chemical Co., Tokyo, 
Japan), and N Antiserum to Human α1-acid Glycoprotein (Siemens Healthcare 
Diagnostics Inc., Marburg, Germany). 
 
Statistical analysis 
All data are expressed as mean ± standard deviation (SD) values. Spearman 
correlation coefficients were used to evaluate whether urinary levels of fetuin-A, 
α1-microglobulin, and orosomucoid correlated with various parameters. To determine 
the variables independently associated with urinary levels of fetuin-A, α1-microglobulin, 
and orosomucoid in the patients with type 2 diabetes, multiple regression analysis was 
performed by including estimated glomerular filtration rate (eGFR), albumin / creatinine 
ratio and HDL cholesterol (HDL-C) as independent variables. Urinary levels of fetuin-A, 
α1-microglobulin, orosomucoid and various clinical parameters in albuminuria and GFR 
stages were compared by Kruskal-Wallis test. Multivariate logistic regression analysis to 
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access the urinary fetuin-A, α1-microglobulin, orosomucoid excretions as a risk for 
diabetic nephropathy with microalbuminuria or with GFR < 60 mL/min. P values less 
than 0.05 were considered statistically significant. Statistical analysis was performed 
with IBM SPSS Statistics Base and IBM SPSS Regression (IBM, Armonk, NY). 
 
Results 
Lectin microarray analyses demonstrated the increased binding activity to 
Siaα2-6-Gal/GalNAc 
We performed lectin microarray analyses and compared the urine samples of the 
healthy subjects without type 2 diabetes (n=12) and the patients with type 2 diabetes 
with various stages of normoalubuminuria (n=7), microalbuminuria (n=5) and 
macroalbuminuria (n=5). The reactivity to the many lectins, such as fucose binder (PSA, 
LCA, AOL, and AAL), Lac/LacNAc binder [PHA(L), ECA, RCA120, PHA(E)], α- or β-Gal 
binder (BPL, ABA, PNA, ACA), chitobiose binder (DSA, LEL, STL, UDA, PWM, WGA), 
and α- or β-GalNAc binder (Jacalin, WFA, MPA, VVA, DBA, SBA, PTL-I, GSL-IA4),  
significantly declined at the stage of macroalbuminuria (Figure 1). Among them, lectins 
which bind to N-glycosylation, RCA120, PHA(E), DSA, demonstrated the increased 
binding activity at the stage of microalbuminuria. Notably, in contrast to majority of the 
lectins, the binding to Siaα2-6-Gal/GalNAc (SNA, SSA, TJA-1) progressively increased 
in the albuminuria stages of diabetic nephropathy (Figure 1, red box). Since we 
identified specific increase in the biding activity to Siaα2-6-Gal/GalNAc in urine samples 
in the patients with diabetic nephropathy, we next screened the sialylated glycoproteins 
in the urine samples of diabetic nephropathy. 
 
Fetuin-A, α1-microglobulin and orosomuioid were identified by SSA-Agarose 
column chromatography and LC/MS-MS analyses 
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   We performed SSA-Agarose column choromatography and the effluents were 
subjected to SDS-PAGE in Supplemental Figure 1. We confirmed that the bands 
visualized with Coomassie Brilliant Blue staining increased in the patients with CKD 
stage of A3G4 compared with the patients A3G3. The effluents were subjected to 
LC/MS-MS and raw data of the proteins hit by Mascot program searching through 
NCBInr and Swiss-Prot database were indicated in Supplemental Tables 2 and 3 in 
the patients with CKD stages of A3G3 and A3G4, respectively. The listed proteins 
demonstrated the contamination of serum major proteins such as albumin, 
immunoglobulins, complements, α1-antitrypsin, transferrin, and haptoglobin. However, 
we identified three sialylated glycoprpteins such as α1-microglobulin (Protein AMBP), 
α1-acid glycoprotein (orosomucoid) and fetuin-A (α2-HS-glycorptein). Fetuin-A15, 
α1-microglobulin16, and orosomucoid17 have been reported as sialylated glycoproteins 
and we further validated the significance of urinary excretion of sialylated glycoproteins 
as biomarkers for diabetic nephropathy. 
 
Elevated urinary fetuin-A excretion is a risk for the development of diabetic 
nephropathy 
We investigated urinary excretion of sialylated glycoproteins in various stages of 
diabetic nephropathy (n=85). In albuminuria stages, age, serum total protein, serum 
albumin, Cr, UN, uric acid, HDL-C, eGFR, ACR were significantly changed revealed by 
Kruskal-Wallis test (Table 1). All of the urinary excretion of sialylated glycoprpteins such 
as fetuin-A, α1-microglobulin, and orosomucoid significantly increased during the 
progression of A1 to A3 stages (Table 1 and Figure 1a-d). During the progression of 
GFR stages, serum total protein, serum albumin, Cr, UN, uric acid, eGFR, and ACR 
were significantly altered by Kruskal-Wallis test (Table 2). Like albuminuria stages, the 
urinary excretion of fetuin-A, α1-microglobulin, and orosomucoid significantly increased 
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in the GFR stages from G1 to G4 revealed by Kruskal-Wallis test (Table 2 and Figure 
1e-h).   
   All of the urinary excretion of fetuin-A, α1-microglobulin, and orosomucoid positively 
correlated with Cr, UN and ACR and negatively correlated with serum albumin, HDL-C 
and eGFR with statistically significant differences (Table 3 and Figure 2). The linear 
regression analyses were followed by a multiple regression analysis using the urinary 
excretion of fetuin-A, α1-microglobulin, and orosomucoid as the dependent variables to 
further analyze the significant predictors (Table 4). eGFR, ACR and HDL-C were used 
as independent variables. eGFR and ACR independently and significantly predicted 
urinary excretion of fetuin-A and α1-microglobulin. For urinary excretion of orosomucoid, 
ACR and HDL-C were significantly determinants in multiple regression models in Table 
4. Finally, multivariate logistic regression analysis was employed to assess three urinary 
sialylated glycoproteins as a risk for diabetic nephropathy with microalbuminuria or GFR 
< 60 mL/min. We used the forward stepwise method and the variable whose addition 
causes the largest statistically significant change in -2 Log Likelihood is added to the 
model. The final models are indicated in Tables 5 and urinary excretion of fetuin-A is 
demonstrated as a risk factor for both microalbuminuria and reduction of GFR in 
diabetic nephropathy with the odds ratio (95% confidence intervals) of 4.721 
(1.881-11.844) and 3.739 (1.785-7.841), respectively.  
 
Discussion 
Glycans have important roles in living organisms with their structural diversity; 
however, glycan profiling studies have not been extensively performed because it is 
technically challenging. Recently, the genome-wide association study identified 
hepatocyte nuclear factor 1-α (HNF1A) as a key regulator of fucosylation and the 
DG9-glycan index, which is the ratio of fucosylated to nonfucosylated triantennary 
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glycans, display altered fucosylation of N-linked glycans on plasma proteins. Thus, the 
glycan biomarkers could improve the efficiency of a diagnosis of HNF1A-MODY18. In 
diabetic nephropathy, Ahn J.M. et al. performed glycan profile of plasma samples from 
normal subjects and the patients with diabetes. They captured glycoproteins by 
multi-lectin affinity chromatography and trypsin-digested glycoproteins were subjected 
to the analysis by LC-MS/MS19. However, no other studies have been reported to 
survey the glycan profile of the urine samples so far, and we believe that the current 
investigation is the first study to perform glycan profiling of urines samples from the 
patients with diabetic nephropathy. As a result, we have found that global reduction of 
the bindings to lectins, such as fucose, Lac/LacNA, α- or β-Gal, chitobiose, and α- or 
β-GalNAc binders in urine samples of diabetic nephropathy at macroalbuminuria stage. 
Unlike the reduced bindings to these lectins, the biding activity to Siaα2-6-Gal/GalNAc 
binders progressively increased at micro- and macroalbuminruia stages. In the patients 
with type 1 diabetes, the reduction of sialidase activities was observe in mononuclear 
leucocytes and they speculated that diabetes-associated changes in sialylation of 
functional cell surface glycolconjugates may have important clinical consequences in 
diabetes20. The analysis of sialylation of insulin-like growth factor-binding protein 
(IGFBP)-3 from the poorly controlled patients with type 2 diabetes, increased binding of 
IGFBP-3 to SNA suggesting increased sialylation of IGFBP321. In contrast, reduced 
α2-6 sialylation of glycodelin-A was observed in gestational diabetes mellitus22. One can 
speculate that the alterations in the expression of sialyltransferases or sialidase may 
influence the sialylation of plasma glycoproteins; however, the status of sialylation 
seems to be complex in the patients with diabetes. Increased sialylated glycoproteins in 
urine samples may also be due to the alteration in the permselectivities of glomerular 
capillary, since sialylated glycoproteins are characterized by negative charge.  
α1-microglobulin, also known as protein HC (for Heterogeneous Charge), was 
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initially suggested as a marker for the detection of proximal tubular dysfunction by 
cadmium poisoning23. α1-microglobulin is a small protein with up to 31 kDa and it is 
filtered through glomeruli and reabsorbed by the proximal tubules24. Urinary excretion of 
α1-microglobulin was significantly higher in the early stages of the disease process, 
while albumin excretion was still in the normal range25. Thus, it may serves as early 
marker for tubular damages in diabetic nephropathy and may precede albumin 
excretion to the urine25-27. Low molecular weight markers of tubular dysfunction such as 
α1-microglobulin, therefore, appear as markers of renal dysfunction that may 
complement markers of glomerular dysfunction such as albumin7. Orosomucoid, α-1 
acid glycoprotein with 41 kDa, is an acute-phase protein and the serum concentrations 
correlated with low-grade inflammation in the patients with diabetes28, 29. Urine excretion 
of orosomucoid was increased in the patients with diabetes and normoalbuminuria and 
it correlated with markers of inflammation such as CRP29-31 and markers for endothelial 
dysfunction32. Type 2 diabetic patients with elevated urinary orosomucoid excretion 
exhibited normal glomerular and tubular function, suggesting the possibility of local 
renal production of orosomucoid due to chronic low-grade inflammation rather than 
hyperfiltration33.  
   Fetuin-A has been principally studied as an inhibitor for ectopic calcium deposition in 
the renal field and it is also an important promoter for insulin resistance. Fetuin-A, a liver 
secretory glycoprotein with 64 kDa, has been shown that it acts as carrier of free fatty 
acids (FFAs) and they are the intrinsic ligands for Toll-like receptor 4 (TLR4), which 
induces adipose tissue inflammation and insulin resistance34. Fetuin-A binds to the 
residues of Leu100-Gly123 and Thr493-Thr516 of TLR4 through the terminal 
galactoside moiety34. Thus, FFA-Fetuin-A induced TLR4 activation is very important in 
the lipid-induced inflammation and insulin resistance and type 2 diabetes. In addition, 
fetuin-A and adiponectin mediate the crosstalk between adipose tissues, liver and 
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kidney. Fetuin-A suppresses mRNA expression of adiponectin in cultured human 
adipocytes and treatment of wild-type mice with fetuin-A lowered serum adiponectin 
levels35. Higher fetuin-A and lower adiponectin levels may contribute the development of 
insulin resistance, diabetes and subsequent obesity-related CKD and diabetic 
nephropathy36. Serum concentration of fetuin-A in type 2 diabetes patients has been 
reported and they positively correlated with macrovascular late complications in 
high-risk type 2 diabetes patients, while no association with metabolic status or 
microvascular complications37. In other studies, lower serum levels of fetuin-A are 
associated with peripheral arterial disease in patients with type 2 diabetes38 and serum 
fetuin-A levels are negatively associated with atherosclerotic calcified plaques39. Thus, 
the significance of serum fetuin-A levels is controversial whether it is a good marker for 
diabetic micro- and macrovascular complications. Here, we first demonstrated that the 
urinary excretion of fetuin-A is a candidate for the biomarker to predict the progression 
of diabetic nephropathy. Urinary concentration of fetuin-A may be depending on the 
production from the liver, alterations in permeability through glomerular basement 
membrane by capillary damages and changes in tubular reabsorption. Thus, higher 
excretion of fetuin-A into urine may reflects the insulin resistance and inflammatory 
responses in obesity and type 2 diabetes and also glomerular capillary and tubular 
damage in the kidney tissues. Actually, multivariate regression analysis indicated that 
higher urinary fetuin-A excretion demonstrated a higher risk for the development of 
microalbuminuria and reduction of renal function and future cohort study is required to 
further confirm this notion.  
  In summary, the glycan profiling studies using urine samples from the patients with 
diabetic nephropathy is useful to identify the new biomarkers to predict the progression 
of diabetic nephropathy. We demonstrated that global reduction of the bindings to 
lectins, such as fucose, Lac/LacNA, α- or β-Gal, chitobiose, and α- or β-GalNAc binders 
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in urine samples of diabetic nephropathy at macroalbuminuria stage, and in contrast 
increased biding activity to Siaα2-6-Gal/GalNAc binders. Further, we identified three 
sialylated glycoprpteins such as α1-microglobulin (Protein AMBP), α1-acid glycoprotein 
(orosomucoid) and fetuin-A (α2-HS-glycorptein) by SSA-Agarose column 
choromatography and LC/MS-MS analysis. Finally, we have newly shown that higher 
urinary excretion of fetuin-A is a risk factor for both microalbuminuria and reduction of 
GFR in diabetic nephropathy. 
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Figure legends 
Figure 1 Lectin microarray analysis using urine samples from the patients with 
various albuminuria stages. Lectin microarray analysis of urine samples were 
performed in the healthy subjects without type 2 diabetes (Control, n=12) and the 
patients with type 2 diabetes with various stages of normoalubuminuria (A1, n=7), 
microalbuminuria (A2, n=5) and macroalbuminuria (A3, n=5). Signals to various lectins 
are compared by Kruskal-Wallis test.  
 
Figure 2 Urinary excretion of fetuin-A, α1-microglobulin, orosomucoid and 
albumin creatinine ratio (ACR) in various stages of diabetic nephropathy (n=85). 
All of the urinary excretion of sialylated glycoprpteins such as fetuin-A, α1-microglobulin, 
and orosomucoid are compared by Kruskal-Wallis test.  
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Figure 3 Simple correlation of urinary excretion of fetuin-A, α1-microglobulin, 
orosomucoid with estimated glomerular filtration ratio (eGFR) and urinary 
albumin creatinine ratio (ACR) in the patients with diabetic nephropathy (n=85). 
Spearman correlation coefficients are used to evaluate whether urinary levels of 
fetuin-A, α1-microglobulin, and orosomucoid correlate with eGFR and ACR. 
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Table 1 Comparison of various parameters in albuminuria stages of chronic 
kidney disease in type 2 diabetes patients (n=85). 
 A1 A2 A3 Total Kruskal-Wallis
Number 
(male/female) 
36 (19 / 17) 25 (15 / 10) 24 (15 / 9) 85 (49 / 36)  
Age (years) 63.8±11.3 61.0±12.5 63.3±12.3 62.9±11.3 0.006* 
BMI (kg/m2) 24.8±5.1 25.7±4.5 24.2±3.9 24.9±4.6 0.543 
SBP (mmHg) 124.0±12.6 129.5±20.5 126.0±19.7 126.2±17.3 0.484 
DBP (mmHg) 73.9±10.3 72.6±8.1 69.1±14.4 72.2±11.1 0.261 
HbA1c (%) 7.31±0.64 7.24±0.90 7.38±1.17 7.31±0.87 0.850 
Total protein (g/L) 70.4±4.3 70.7±4.8 66.1±6.5 69.3±5.4 0.003* 
Albumin (g/L) 42.9±2.5 41.2±3.2 35.7±7.0 40.4±5.3 1.80x10-16** 
Cr (μmol/L) 66.4±13.3 78.3±26.3 144.2±70.3 91.9±52.3 4.86x10-10** 
UN (μmol/L) 5.5±1.5 7.1±2.7 10.0±3.8 7.3±3.3 5.92x10-8** 
Uric acid (μmol/L) 305.8±61.5 352.8±96.2 396.2±68.0 344.6±83.1 9.68x10-5** 
T-Cho (mmol/L) 5.09±0.94 4.86±0.84 5.06±1.14 4.99±0.97 0.689 
TG (mmol/L) 1.65±0.92 1.70±1.10 2.16±1.74 1.81±1.26 0.780 
HDL-C (mmol/L) 1.49±0.41 1.35±0.31 1.23±0.39 1.38±0.39 0.031* 
LDL-C (mmol/L) 2.85±0.81 2.70±0.65 2.80±0.95 2.79±0.80 0.271 
eGFR (mL/min) 74.5±16.3 67.9±19.2 42.4±19.0 63.5±22.4 6.66x10-9** 
ACR (mg/gCr) 12.7±6.0 114.3±72.6 1424±996 441.2±812 1.81x10-16** 
Fetuin-A (ng/gCr) 0.40±0.43 0.60±0.53 1.57±1.13 0.79±0.87 7.29x10-8** 
α1-microglobulin 
(ng/gCr) 
4.24±4.03 6.30±5.12 17.83±18.08 8.68±11.74 8.84x10-9** 
Orosomucoid 
(ng/gCr) 
17.5±9.1 17.9±8.7 91.4±87.2 38.5±57.0 3.34x10-8** 
BMI, body mass index; SBP, Systolic Blood Pressure; DPB, Diastolic Blood Pressure; Cr, 
serum creatinine; UN, serum urea nitrogen; T-Cho, Total cholesterol; TG, Triglyceride; 
HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; eGFR, estimated glomerular filtration 
ratio; ACR, albumin / creatinine ratio; *, p < 0.05; **, p < 0.01. 
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Table 2 Comparison of various parameters in glomerular filtration stages of 
chronic kidney disease in type 2 diabetes patients (n=85). 
 G1 G2 G3 G4 Total Kruskal-Wallis
Number 
(male/female) 
9 (6 / 3) 42 (22 / 20) 29 (19 / 10) 5 (2 / 3) 85 (49 / 36)  
Age (years) 51.9±13.9 62.9±10.3 66.5±9.2 59.6±15.3 62.9±11.3 0.647 
BMI (kg/m2) 27.6±8.1 25.1±4.6 24.1±3.1 22.6±2.2 24.9±4.6 0.155 
SBP (mmHg) 129.7±13.8 127.6±17.3 124.0±19.1 120.2±11.1 126.2±17.3 0.640 
DBP (mmHg) 76.5±13.8 74.6±8.0 69.5±12.4 59.4±9.2 72.2±11.1 0.006 
HbA1c (%) 7.54±0.79 7.27±0.83 7.40±0.94 6.68±0.82 7.31±0.87 0.323 
Total protein (g/L) 70.4±3.7 70.9±4.4 67.6±6.2 63.0±5.0 69.3±5.44 0.002* 
Albumin (g/L) 41.4±4.6 42.3±2.9 38.3±6.6 33.4±5.0 40.4±5.3 1.10x10-4** 
Cr (μmol/L) 60.9±16.0 65.9±11.6 115.7±40.7 227.1±88.2 91.9±52.3 1.89 x10-17** 
UN (μmol/L) 5.5±2.2 5.8±1.6 8.6±2.7 14.6±5.1 7.3±3.3 9.85x10-12** 
Uric acid (μmol/L) 329.1±39.5 312.8±74.4 388.7±82.6 391.4±99.8 344.6±83.1 6.59 x10-4** 
T-Cho (mmol/L) 5.11±0.96 4.97±0.89 5.06±1.02 4.52±1.39 4.99±0.97 0.695 
TG (mmol/L) 2.04±1.30 1.68±1.06 1.95±1.57 1.58±0.63 1.81±1.26 0.487 
HDL-C (mmol/L) 1.25±0.26 1.44±0.37 1.32±0.41 1.45±0.51 1.38±0.39 0.427 
LDL-C (mmol/L) 2.96±0.95 2.79±0.67 2.83±0.92 2.28±0.87 2.79±0.80 0.740 
eGFR (mL/min) 96.2±15.6 74.8±8.1 44.4±9.2 20.6±8.3 63.5±22.4 1.16x10-30** 
ACR (mg/gCr) 179.7±451.6 108.3±227.7 824.5±0.80 1484±1168 441.2±812 1.09x10-5** 
Fetuin-A (ng/gCr) 0.39±0.39 0.49±0.45 1.25±1.18 1.34±0.80 0.79±0.87 3.89x10-4** 
α1-microglobulin 
(ng/gCr) 
3.74±4.26 4.94±4.92 11.90±11.04 30.32±29.93 8.68±11.74 2.49x10-6** 
Orosomucoid 
(ng/gCr) 
22.5±11.4 19.7±14.8 62.7±84.3 84.4±69.4 38.5±57.0 2.21x10-3** 
BMI, body mass index; SBP, Systolic Blood Pressure; DPB, Diastolic Blood Pressure; Cr, 
serum creatinine; UN, serum urea nitrogen; T-Cho, Total cholesterol; TG, Triglyceride; 
HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; eGFR, estimated glomerular filtration 
ratio; ACR, albumin / creatinine ratio; *, p < 0.05; **, p < 0.01. 
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Table 3 Simple correlation of urinary sialylated glycoprotein excretions with 
various clinical parameters in the patients with type 2 diabetes (n=85) 
 
 Fetuin-A (ng/gCr) α1-microglobulin (ng/gCr) Orosomucoid (ng/gCr) 
Age (years) R=0.009, p=0.937 R=0.123, p=0.261 R=-0.008, p=0.944 
BMI (kg/m2) R=-0.139, p=0.205 R=-0.067, p=0.541 R=-0.032, p=0.770 
SBP (mmHg) R=0.043, p=0.693 R=-0.005, p=0.964 R=0.103, p=0.348 
DBP (mmHg) R=-0.145, p=0.186 R=-0.214, p=0.049* R=-0.027, p=0.807 
HbA1c (%) R=0.113, p=0.307 R=0.110, p=0.318 R=0.056, p=0.612 
Total protein (g/L) R=-0.261, p=0.017* R=-0.275, p=0.012* R=-0.213, p=0.053 
Albumin (g/L) R=-0.377, p=4.36x10-4** R=-0.376, p=4.67x10-4** R=-0.394, p=2.28x10-4** 
Cr (μmol/L) R=0.368, p=5.23x10-4** R=0.388, p=2.40x10-4** R=0.399, p=1.53x10-4** 
UN (μmol/L) R=0.405, p=1.31x10-4** R=0.439, p=2.96x10-5** R=0.363, p=6.85x10-4** 
Uric acid (μmol/L) R=0.079, p=0.474 R=0.073, p=0.509 R=0.295, p=0.006** 
T-Cho (mmol/L) R=-0.099, p=0.372 R=-0.080, p=0.471 R=0.062, p=0.576 
TG (mmol/L) R=0.060, p=0.582 R=0.055, p=0.615 R=0.186, p=0.088 
HDL-C (mmol/L) R=-0.313, p=0.004** R=-0.258, p=0.017* R=-0.244, p=0.025* 
LDL-C (mmol/L) R=-0.007, p=0.948 R=-0.043, p=0.697 R=0.067, p=0.544 
eGFR (mL/min) R=-0.395, p=1.80x10-4** R=-0.472, p=5.23x10-6** R=-0.431, p=3.90x10-5** 
ACR (mg/gCr) R=0.548, p=5.76x10-8** R=0.466, p=7.02x10-6** R=0.652, p=1.40x10-11** 
BMI, body mass index; SBP, Systolic Blood Pressure; DPB, Diastolic Blood Pressure; Cr, 
serum creatinine; UN, serum urea nitrogen; T-Cho, Total cholesterol; TG, Triglyceride; 
HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; eGFR, estimated glomerular filtration 
ratio; ACR, albumin / creatinine ratio; *, p < 0.05; **, p < 0.01. 
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Table 4 Multiple linear regression analysis using urinary sialylated glycoprotein 
excretions as dependent variables in the patients with type 2 diabetes (n=85). 
Dependent 
variable 
Independent 
variable 
Unstandardized 
coefficient 
Standardized 
coefficient 
t value P value 
Adjusted 
R2 
B 
Standard 
Error 
Beta 
Fetuin-A (ng/gCr) eGFR (mL/min) 
ACR (mg/gCr) 
HDL-C (mmol/L) 
-0.076 
0.004 
-4.048 
0.042 
0.001 
2.035 
-0.196 
0.395 
-0.182 
-1.813 
3.645 
-1.989 
0.074 
4.71x10-4** 
0.050 
0.335 
α1-microglobulin 
(ng/gCr) 
eGFR (mL/min) 
ACR (mg/gCr) 
HDL-C (mmol/L) 
-0.138 
0.007 
-1.443 
0.053 
0.001 
2.548 
-0.263 
0.461 
-0.048 
-2.617 
4.560 
-0.566 
0.011* 
4.71x10-5 
0.573 
0.423 
Orosomucoid 
(ng/gCr) 
eGFR (mL/min) 
ACR (mg/gCr) 
HDL-C (mmol/L) 
-0.136 
0.049 
-26.65 
0.212 
0.006 
10.240 
-0.053 
0.703 
-0.183 
-0.642 
8.405 
-2.603 
0.523 
1.19x10-12**
0.011 
0.605 
Estimated glomerular filtration rate (eGFR), albumin / creatinine ratio and HDL cholesterol 
(HDL-C) are used as independent variables in stepwise multiple linear regression analysis 
in model 1. In model 2, all parameters are included in the analysis. *, p < 0.05; **, p < 0.01. 
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Table 5 Stepwise multivariate logistic regression analysis to assess the urinary 
sialylated glycoprotein excretions as a risk for diabetic nephropathy with 
microalbuminuria or glomerular filtration rate (GFR) < 60 ml/min. 
Risk factor for 
microalbuminuria 
B 
Standard 
error 
p 
Odds ratio (95% 
confident intervals) 
Predictive accuracy 
Fetuin-A (ng/gCr) 
(1SD increments) 
1.784 0.539 9.424x10-4** 4.721 (1.881-11.844) 74.1% 
      
Risk factor for GFR < 60 
mL/min 
B 
Standard 
error 
p 
Odds ratio (95% 
confident intervals) 
Predictive accuracy 
Fetuin-A (ng/gCr) 
(1SD increments) 
1.516 0.434 4.755x10-4** 3.739 (1.785-7.841) 72.9% 
**, p < 0.01. 
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Supplemental Figure 1
SSA-Agarose column choromatography was
performed in the 4 patients with type 2 diabetes.
The patients demonstrated various albuminria
and GFR stages; A3G3 and A3G4. The effluents
were subjected to SDS-PAGE.
Supplemental Table 1 A list of lectins of LecChipTMVer.1 and the specificity. 
Lectin 
No. 
Lectin Origin Reported specificity 
1 LTL Lotus tetragonolobus Fuc α1-3(Galβ1-4)GlcNAc, Fuc α1-2Galβ1-4GlcNAc 
2 PSA Pisum sativum Fuc α1-6GlcNAc, α-D-Glc, α-D-Man 
3 LCA Lens culinaris Fuc α1-6GlcNAc, α-D-Glc, α-D-Man 
4 UEA-I Ulex europaeus Fuc α1-2Galβ1-4GlcNAc 
5 AOL 
Aspergillus oryzae 
l-fucose-specific lectin  
Fuc α1-6GlcNAc (core fucose) 
6 AAL Aleuria aurantia Fuc α1-6GlcNAc, Fuc α1-3(Galβ1-4)GlcNAc 
7 MAL Maackia amurensis Siaα2-3Galβ1-4GlcNAc 
8 SNA Sambucus nigra Siaα2-6Gal/GalNAc 
9 SSA Sambucus sieboldiana Siaα2-6Gal/GalNAc 
10 TJA-I Trichosanthes japonica Siaα2-6Gal/GalNAc 
11 PHAL Phaseolus vulgaris tri/tetra-antennary complex-type N-glycan 
12 ECA Erythrina cristagalli Galβ1-4GlcNAc 
13 RCA120 Ricinus communis Galβ1-4GlcNAc 
14 PHAE Phaseolus vulgaris 
bi-antennary complex-type N-glycan with outer Gal and 
bisecting GlcNAc 
15 DSA Datura stramonium (GlcNAc β1-4)n, Galβ1-4GlcNAc 
16 GSL-II Griffonia simplicifolia agalactosylated tri/tetra antennary glycans, GlcNAc 
17 NPA 
Narcissus 
pseudonarcissus 
High-Mannose, Man α1-6Man 
18 ConA Canavalia ensiformis High-Mannose, Man α1-6(Manα1-3)Man 
19 GNA Galanthus nivalis High-Mannose,  Manα1-3Man 
20 HHL Hippeastrum hybrid High-Mannose,  Manα1-3Man, Manα1-6Man 
21 ACG Agrocybe cylindracea Siaα2-3Galβ1-4GlcNAc 
22 TxLCI Tulipa gesneriana 
Man α1-3(Manα1-6)Man, bi- and tri-antennary 
complex-type N-glycan, GalNAc 
23 BPL Bauhinia purpurea alba Galβ1-3GalNAc, GalNAc 
24 TJA-II Trichosanthes japonica 
Fuc α1-2Galβ1-> or GalNAc β1-> groups at their 
nonreducing terminals 
25 EEL Euonymus europaeus blood group B antigen,  Galα1-3Gal 
26 ABA Agaricus bisporus Galβ1-3GalNAc 
27 LEL Lycopersicon esculentum GlcNAc trimers/tetramers 
28 STL Solanum tuberosum 
GlcNAc oligomers, oligosaccharide containing GlcNAc 
and MurNAc 
29 UDA Urtica dioica GlcNAc β1-4GlcNAc, Mixture of Man5 to Man9 
30 PWM Phytolacca americana (GlcNAc β1-4)n 
31 Jacalin Artocarpus integrifolia Galβ1-3GalNAc, GalNAc 
32 PNA Arachis hypogaea Galβ1-3GalNAc 
33 WFA Wisteria floribunda GalNAc β1-4GlcNAc, Galβ1-3(-6)GalNAc 
34 ACA Amaranthus caudatus Galβ1-3GalNAc 
35 MPA Maclura pomifera Galβ1-3GalNAc, GalNAc 
36 HPA Helix pomatia agglutinin α-linked terminal GalNAc 
37 VVA Vicia villosa α-linked terminal GalNAc, GalNAc α1-3Gal 
38 DBA Dolichos biflorus blood group A antigen, GalNAc α1-3GalNAc 
39 SBA Glycine max α- or β-linked termincal GalNAc, GalNAc α1-3Gal 
40 Calsepa Calystegia sepium Mannose, Maltose 
41 PTL-I 
Psophocarpus 
tetragonolobus 
α-linked terminal GalNAc 
42 MAH Maackia amurensis Siaα2-3Galb1-3(Siaα2-6)GalNAc 
43 WGA Triticum unlgaris chitin oligomers, Sia 
44 
GSL-I 
A4 
Griffonia simplicifolia 
Lectin I Isolectin A4 
α-linked GalNAc 
45 
GSL-I 
B4 
Griffonia simplicifolia 
Lectin I Isolectin B4 
α-linked Gal 
These data were collected from lectin vendors and reports found by internet searches. 
  
 Supplemental Table 2 Liquid chromatography–tandem mass spectrometer (LC/MS-MS) of samples from 
the patients with A3G3 and the search result through NCBInr and Swiss-Prot database performed by 
Mascot.   
Pos. Ac.No. Protein Name Sequences emPAI*1 Score*2 
1 ALBU_HUMAN Serum albumin  36 11.04 3985 
2 TRFE_HUMAN Serotransferrin  15 1.08 965 
3 AMBP_HUMAN Protein AMBP (alpha 1-microglobulin) 5 0.57 224 
4 VTDB_HUMAN Vitamin D-binding protein  3 0.14 130 
5 HEMO_HUMAN Hemopexin  3 0.23 112 
6 PTGDS_HUMAN Prostaglandin-H2 D-isomerase  1 0.18 75 
7 IGKC_HUMAN Ig kappa chain C region  1 0.34 70 
8 HPT_HUMAN Haptoglobin  3 0.17 63 
9 DTX3L_HUMAN E3 ubiquitin-protein ligase DTX3L 1 0.04 49 
10 CLUS_HUMAN Clusterin  1 0.07 39 
11 SAP_HUMAN Proactivator polypeptide  1 0.06 34 
12 A1AT_HUMAN Alpha-1-antitrypsin  2 0.08 33 
13 AFAM_HUMAN Afamin  2 0.05 32 
14 FETUA_HUMAN Alpha-2-HS-glycoprotein (Fetuin-A) 1 0.09 29 
15 THRB_HUMAN Prothrombin  1 0.05 25 
16 TRPC4_HUMAN Short transient receptor potential channel 4 1 0.03 20 
17 RABE1_HUMAN Q15276 2 0.04 19 
18 MARK1_HUMAN Serine/threonine-protein kinase MARK1  1 0.04 16 
*1: emPAI (Exponentially Modified Protein Abundance Index) is calculated for the estimation of absolute 
protein amount as follow; 
    
 
*2: Probability Based Mowse Score. Ions score is -10*Log(P), where P is the probability that the 
observed match is a random event. Individual ions scores > 16 indicate identity or extensive homology 
(p<0.05). 
 
 
 
  
Supplemental Table 3 Liquid chromatography–tandem mass spectrometer (LC/MS-MS) of samples 
from the patients with A3G4 and the search result through NCBInr and Swiss-Prot database performed by 
Mascot. 
Pos. Ac.No. Protein Name Sequences emPAI Score*1 
1 ALBU_HUMAN Serum albumin  52 21.13 3829 
2 TRFE_HUMAN Serotransferrin  23 1.61 800 
3 HPT_HUMAN Haptoglobin 17 3.1 683 
4 IGHG1_HUMAN  Ig gamma-1 chain C region 10 2.56 601 
5 IGHG2_HUMAN Ig gamma-2 chain C region 8 0.99 227 
6 IGKC_HUMAN Ig kappa chain C region 6 4.73 516 
7 IGHA1_HUMAN Ig alpha-1 chain C region 10 1.54 422 
8 A2MG_HUMAN Alpha-2-macroglobulin  18 0.46 417 
9 A1AT_HUMAN Alpha-1-antitrypsin  10 1.16 392 
10 APOA1_HUMAN Apolipoprotein A-I  8 1.53 251 
11 AMBP_HUMAN Protein AMBP (alpha 1-microglobulin) 7 0.88 226 
12 HEMO_HUMAN Hemopexin  7 0.62 214 
13 LAC2_HUMAN Ig lambda-2 chain C regions 4 1.45 204 
14 CO4A_HUMAN Complement C4-A  2 0.04 147 
15 CERU_HUMAN Ceruloplasmin  2 0.06 127 
16 IC1_HUMAN Plasma protease C1 inhibitor  4 0.22 94 
17 A1BG_HUMAN Alpha-1B-glycoprotein  1 0.07 94 
18 PTGDS_HUMAN Prostaglandin-H2 D-isomerase  1 0.18 94 
19 A1AG1_HUMAN Alpha-1-acid glycoprotein 1 (orosomucoid) 3 0.56 82 
20 ANGT_HUMAN Angiotensinogen  1 0.07 74 
21 ANT3_HUMAN Antithrombin-III  2 0.07 72 
22 KNG1_HUMAN Kininogen-1 2 0.05 71 
23 FETUA_HUMAN Alpha-2-HS-glycoprotein (Fetuin-A) 1 0.09 70 
24 PGRP2_HUMAN N-acetylmuramoyl-L-alanine amidase  1 0.06 62 
25 CO3_HUMAN Complement C3 5 0.02 55 
26 THRB_HUMAN Prothrombin 1 0.05 31 
27 VTDB_HUMAN Vitamin D-binding protein  1 0.07 30 
28 MTUS1_HUMAN Microtubule-associated tumor suppressor 1 1 0.03 26 
*1: emPAI (Exponentially Modified Protein Abundance Index) is calculated for the estimation of absolute 
protein amount as follow; 
    
*2: Probability Based Mowse Score. Ions score is -10*Log(P), where P is the probability that the 
observed match is a random event. Individual ions scores > 16 indicate identity or extensive homology 
(p<0.05). 
 
